Literature DB >> 16211543

Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis.

Andrea B Kramer1, Sharon D Ricardo, Darren J Kelly, Femke Waanders, Harry van Goor, Gerjan Navis.   

Abstract

Proteinuria is associated with macrophage-dependent interstitial fibrosis (IF). Osteopontin (OPN), a macrophage chemoattractant, may be involved in the transition of proteinuria to IF but protective properties have also been reported. To elucidate whether OPN may be involved in the proteinuria-induced cascade of tubulointerstitial damage, renal expression of OPN was studied during the development of proteinuria-induced renal damage and during anti-proteinuric intervention with ACE inhibition (ACEi). First, the temporal relationships between proteinuria, interstitial OPN induction, and IF in adriamycin nephrosis (AN), a model of chronic proteinuria-induced renal damage, were studied. Second, the effect of anti-proteinuric treatment on OPN expression was investigated. The time course of OPN induction and markers of renal damage was studied in rats with unilateral AN at 6-week intervals until week 30. In a second study, a renal biopsy was taken 6 weeks after induction of bilateral AN; subsequently, rats were treated with ACEi until termination (week 12). In unilateral AN, proteinuria developed gradually and stabilized at week 10. In proteinuric kidneys, OPN expression was induced from week 12 onwards. Simultaneously, a progressive increase in interstitial macrophages, alpha-smooth muscle actin (alpha-SMA), collagen type III, and focal glomerulosclerosis (FGS) was observed. In bilateral AN, ACEi reduced proteinuria and OPN protein and stabilized fibrosis. In untreated animals, OPN mRNA increased, with stable OPN protein and fibrosis and increased FGS. Thus, in AN, development of proteinuria is followed by up-regulation of OPN along with markers of renal damage. The up-regulation of OPN is reversible by anti-proteinuric treatment without a corresponding reduction in fibrosis. Whereas these data are consistent with a role for OPN in the cascade of transition from proteinuria to fibrosis, intervention with ACEi showed that reduction of OPN does not attenuate established fibrosis. Copyright 2005 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16211543     DOI: 10.1002/path.1856

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  5 in total

1.  Osteopontin circulating levels correlate with renal involvement in systemic lupus erythematosus and are lower in ACE inhibitor-treated patients.

Authors:  Marco Quaglia; Annalisa Chiocchetti; Tiziana Cena; Claudio Musetti; Sara Monti; Nausicaa Clemente; Umberto Dianzani; Corrado Magnani; Piero Stratta
Journal:  Clin Rheumatol       Date:  2014-05-13       Impact factor: 2.980

2.  Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE.

Authors:  Lina Wirestam; Martina Frodlund; Helena Enocsson; Thomas Skogh; Jonas Wetterö; Christopher Sjöwall
Journal:  Lupus Sci Med       Date:  2017-07-28

3.  Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis.

Authors:  Katarina Mirković; Carolina R C Doorenbos; Wendy A Dam; Hiddo J Lambers Heerspink; Maartje C J Slagman; Ferdau L Nauta; Andrea B Kramer; Ronald T Gansevoort; Jacob van den Born; Gerjan Navis; Martin H de Borst
Journal:  PLoS One       Date:  2013-02-11       Impact factor: 3.240

4.  Proteinuria triggers renal lymphangiogenesis prior to the development of interstitial fibrosis.

Authors:  Saleh Yazdani; Fariba Poosti; Andrea B Kramer; Katarina Mirković; Arjan J Kwakernaak; Menno Hovingh; Maartje C J Slagman; Klaas A Sjollema; Martin H de Borst; Gerjan Navis; Harry van Goor; Jacob van den Born
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

5.  Association between Osteopontin Promoter Gene Polymorphisms and Haplotypes with Risk of Diabetic Nephropathy.

Authors:  Balneek Singh Cheema; Sreenivasa Iyengar; Rajni Sharma; Harbir Singh Kohli; Anil Bhansali; Madhu Khullar
Journal:  J Clin Med       Date:  2015-06-10       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.